On March 28, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, reported the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California (Press release, Revolution Medicines, MAR 28, 2024, View Source [SID1234641576]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:
Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor
Presenter:
John Knox, Ph.D.
Abstract Number:
ND03
Session: New Drugs on the Horizon: Part 1
Date/Time: 1:45 – 2:00 p.m. PT on April 7, 2024

Title: RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor
Presenter: Elena Koltun, Ph.D., Wei Lin, M.D.
Session: KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology
Date/Time: 1:00 – 1:20 p.m. PT on April 9, 2024

Title: Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC
Presenter: Xing Wei, Ph.D.
Abstract Number: 6585
Session: Novel Antitumor Agents 5
Date/Time: 2:35 – 2:50 p.m. PT on April 9, 2024

Revolution Medicines Poster Presentations:

Title:
Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models
Presenter:
Lillian Seu, Ph.D.
Abstract Number:
581/4
Session: Immunotherapy
Date/Time: 1:30 – 5:00 p.m. PT on April 7, 2024

Title: RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors
Presenter: Zhe Chen, M.B.B.S., Ph.D.
Abstract Number: 3340/28
Session: Novel Antitumor Agents 3
Date/Time: 1:30 – 5:00 p.m. PT on April 8, 2024

Title: The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers
Presenter: Priyanka Bapat, Ph.D.
Abstract Number: 4709/2
Session: Other Cellular Mechanisms for Anticancer Drug Action
Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 9, 2024

Collaborator Poster Presentations:

Title:
RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models
Lead RevMed Co-Author: Harshit Shah, Ph.D.
Abstract Number:
1924/2
Session: Drug Resistance 2: RAS GTPase
Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024

Title: Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors
Lead RevMed Co-Author: Jingjing Jiang, Ph.D.
Abstract Number: 1927/5
Session: Drug Resistance 2: RAS GTPase
Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024

Additional information on the AACR (Free AACR Whitepaper) Annual Meeting 2024 is available through the AACR (Free AACR Whitepaper) website at: View Source